• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    eXoZymes Inc. - Common Stock (NQ:EXOZ)

    5.810 +0.270 (+4.87%)
    Delayed Quote Updated: 12:56 PM EDT, Oct 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about eXoZymes Inc. - Common Stock

    < Previous 1 2 Next >
    Water Tower Research Publishes Initiation of Coverage Report on eXoZymes, Inc., "Converting Cell-Free Science into a Scalable and Repeatable Commercial Opportunity"
    October 2, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on eXoZymes, Inc. (NASDAQ: EXOZ) titled, “Converting Cell-Free... 
    Via TheNewswire.com
    Topics Initial Public Offering
    News headline image
    eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT
    Program expected to commence in Q4 2026 and establish a roadmap for larger-scale production in 2027 
    From eXoZymes
    Via ACCESS Newswire
    News headline image
    Investor Summit | MicroCap Opportunities to Watch - August 26
    From Investor Summit Group
    Via ACCESS Newswire
    News headline image
    eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today
    From eXoZymes
    Via ACCESS Newswire
    News headline image
    eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets
    From eXoZymes
    Via ACCESS Newswire
    News headline image
    eXoZymes Provides Fourth Quarter and Full Year 2025 Update
    Via ACCESS Newswire
    News headline image
    eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026
    From eXoZymes
    Via ACCESS Newswire
    News headline image
    eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing
    From eXoZymes
    Via ACCESS Newswire
    News headline image
    Q2 Virtual Investor Summit Presentations Now Available On Demand
    From Investor Summit Group
    Via ACCESS Newswire
    News headline image
    eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery
    From eXoZymes
    Via ACCESS Newswire
    News headline image
    eXoZymes Inc. Announces Closing of $6 Million Public Offering
    From eXoZymes
    Via ACCESS Newswire
    News headline image
    eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants
    Via ACCESS Newswire
    News headline image
    eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program
    Via ACCESS Newswire
    News headline image
    eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast
    Via ACCESS Newswire
    News headline image
    eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026
    Via ACCESS Newswire
    News headline image
    Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability
    Via ACCESS Newswire
    News headline image
    eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium
    Via ACCESS Newswire
    News headline image
    With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation
    Via ACCESS Newswire
    News headline image
    eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run
    Via ACCESS Newswire
    News headline image
    eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion
    Via ACCESS Newswire
    News headline image
    eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today
    Via ACCESS Newswire
    News headline image
    eXoZymes Announces Cell-Free Biomanufacturing Pioneer, Tyler Korman, As CSO & Amy Lunzer as Chief of Staff
    Via ACCESS Newswire
    News headline image
    eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST
    Via ACCESS Newswire
    News headline image
    CEO of eXoZymes on 'AI in Life Sciences' panel at the Beryl Elites' Investment Conference
    Via ACCESS Newswire
    News headline image
    CEO of eXoZymes to Present at Spartan Capital Securities' Second Annual Investor Conference
    Via ACCESS Newswire
    News headline image
    CEO of eXoZymes to Present at ThinkEquity's Annual Investor Conference
    Via ACCESS Newswire
    News headline image
    Driving the Cell-Free Revolution: eXoZymes Leaders Join BioMADE Leadership & Technical Committees
    Via ACCESS Newswire
    News headline image
    eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today
    Via ACCESS Newswire
    News headline image
    eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST
    Via ACCESS Newswire
    News headline image
    eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity
    Via ACCESS Newswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.